Company Filing History:
4 out of 6 
3 out of 3,390 
2 out of 832,912 Years Active: 1997-2003
Title: Mark S Kaminski: Innovator in Radioimmunotherapy
Introduction
Mark S Kaminski is a prominent inventor based in Ann Arbor, MI (US). He has made significant contributions to the field of medical treatments, particularly in the area of lymphoma therapy. With a total of 6 patents to his name, Kaminski's work has had a profound impact on cancer treatment methodologies.
Latest Patents
One of Kaminski's latest patents focuses on radioimmunotherapy of lymphoma using anti-CD20 antibodies. This invention describes methods for treating lymphoma by administering a B cell-specific antibody. The approach involves providing patients with both unlabeled antibodies and those labeled with a radioisotope. A principal advantage of this method is that it allows for tumor responses to be achieved within a radiometric dose range that does not necessitate hematopoietic stem cell replacement as an adjunct therapy.
Career Highlights
Throughout his career, Mark S Kaminski has worked with notable organizations, including Coulter Pharmaceutical, Inc. and the University of Michigan. His experience in these institutions has contributed to his expertise in developing innovative treatment methods for lymphoma.
Collaborations
Kaminski has collaborated with esteemed colleagues such as Gregory M Butchko and Stephan D Glenn. These partnerships have further enhanced his research and development efforts in the field of radioimmunotherapy.
Conclusion
Mark S Kaminski is a distinguished inventor whose work in radioimmunotherapy has paved the way for advancements in lymphoma treatment. His innovative approaches continue to influence the medical field and improve patient outcomes.